By Krishna N. Das NEW DELHI (Reuters) - Indian doctors and politicians on Thursday welcomed efficacy data for a state-backed coronavirus vaccine that .
Efficacy data for India s own coronavirus vaccine could boost its public acceptance
SECTIONS
Last Updated: Mar 04, 2021, 03:18 PM IST
Share
Synopsis
Any boost to the vaccine s acceptance in India, which on Thursday reported a new COVID-19 cases at their highest in five weeks, could also brighten its export prospects. Bharat Biotech said 40 countries were interested in COVAXIN.
Bharat Biotech Covaxin Efficacy Data: How effective is the vaccine?
Indian doctors and politicians on Thursday welcomed efficacy data for a state-backed coronavirus vaccine that was given emergency approval in January without the completion of a late-stage trial, making people reluctant to receive the shot.
Government data shows that only 10% of about 12.6 million people immunised in India have taken the COVAXIN shot, which was found to be 81% effective in an interim analysis of the late-stage trial, its developer Bharat Biotech said
Indian doctors and politicians welcomed efficacy data for a state-backed coronavirus vaccine that was given emergency approval in January without the completion of a late-stage trial, making people reluctant to receive the shot.
Indian doctors and politicians on Thursday welcomed efficacy data for a state-backed coronavirus vaccine that was given emergency approval in January without the completion of a late-stage trial, making people reluctant to receive the shot.